NOX

1.52%

6.7¢ noxopharm limited

Wonder Drug, page-2

First 2 Last

Share
Profile

Follow
applefoot

392 Posts.

132

23/08/21

11:49

Post #: 55494686
Share
Originally posted by RBx ↑

In NOXCOVID, 37 of 38 patients achieved the equivalent of a Complete Response.

Veyonda continues to rack up impressive data. We know about LuPIN results, in which median survival of 19.7 months was achieved in patients with metastatic CRPC; we know about DARRT-1 results, which generated a number of abscopal responses in end-stage prostate patients; we know that its combination with chemo enabled the carboplatin dose to be reduced to non-toxic levels without affecting efficacy; and now we know that 37 of 38 COVID patients with moderate disease were virtually free of the disease after 14 days.

It is true that larger clinical trials are required, but the evidence so far suggests that Veyonda improves the performance of cancer treatments, and that the same drug has anti-inflammatory properties that benefit patients hospitalized with moderate COVID-19.

By dissolving Idronoxil in a propriety suppository base, Noxopharm has achieved a half-life of over 10 hours for Veyonda, which means that it only needs to be administer twice per day to have 24 hour coverage at therapeutic dose levels.

Using a suppository might not appeal to everyone, but consider this:

If it works, who cares?

Veyonda is SAFE to use

It can be self-administered at home

The unvaccinated will face the threat of death or serious infection for years to come

The action of Veyonda against key cytokines appears able to prevent long-COVID, which threatens to be the worst effect of the COVID-19 virus.

The likely affordability of Veyonda means that it could be widely used as a preventative.

Happy days!

Expand

Excellent roundup of progress to date RBx.

A timely reminder of the stand-out points that are arriving thick and fast…. not only on cancer but now on Covid too. SO FAST it transpires that since you penned this post earlier today….. we now have another extremely interesting piece of news regarding Veyonda and the new TBK1 target.

Oh well!!…. Newsflow has to be continuously updated I guess ….. to be so aptly named. Here’s hoping you will forever be just one step behind…. ‘Cos that will mean it just keeps on coming mate. (grin)

Apples
NOX Price at posting: 58.0¢ Sentiment: Buy Disclosure: Held
8 Upvote

0 Great analysis

Reply

Top Stories

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

ASX hits all time high out the gate on Friday trades following bullish US inflation data

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Bitcoin investors need to know the risks

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

There are more pages in this discussion • 28 more messages in this thread...

First 2 Last

Add NOX (ASX) to my watchlist

(20min delay)
Last 6.7¢		Change 0.001(1.52%)		Mkt cap ! $19.57M

Open	High	Low	Value	Volume
6.7¢	6.7¢	6.7¢	$818	12.21K

Buyers (Bids)

No.	Vol.	Price($)
1	17790	6.7¢

Sellers (Offers)

Price($)	Vol.	No.
7.0¢	4049	1

View Market Depth

No.	Vol.	Price($)
1	17790	0.067
1	24715	0.066
1	15000	0.065
1	10000	0.064
1	100000	0.062

Price($)	Vol.	No.
0.070	4049	1
0.079	11999	1
0.080	12099	2
0.081	22345	2
0.090	52000	3

Last trade - 15.44pm 12/07/2024 (20 minute delay)

NOX (ASX) Chart

Wonder Drug, page-2

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Immutep reports strong response rate from immunotherapies treating carcinomas

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Bitcoin investors need to know the risks

Almonty locks in govt agreement for tungsten oxide plant in South Korea

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Wonder Drug, page-2

Top Stories

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

ASX hits all time high out the gate on Friday trades following bullish US inflation data

Immutep reports strong response rate from immunotherapies treating carcinomas

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Bitcoin investors need to know the risks

Almonty locks in govt agreement for tungsten oxide plant in South Korea

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Week 27 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News